🎁 Black Friday: up to 50% off of annual plans
Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
101.50
-10.00 (-8.97%)
Nov 20, 2026, 1:30 PM CST

Lotus Pharmaceutical Cash Flow Statement

Millions TWD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
2,2234,7205,0664,1063,0211,403
Depreciation & Amortization
2,3871,5261,2731,200926.96748.76
Other Amortization
9.299.4210.1310.239.9110.62
Loss (Gain) From Sale of Assets
-12.9113.720.724.75-2.523.2
Asset Writedown & Restructuring Costs
89.42303.02159.99179.37136.67234.82
Loss (Gain) From Sale of Investments
-253.58-548.28-604.16-715.05-286.81-
Stock-Based Compensation
232.37279.38348.65106.4939.4157.66
Provision & Write-off of Bad Debts
36.85-7.61-2.96-4.04-3.3334.24
Other Operating Activities
409.03-572.03615.83144.35788.08460.19
Change in Accounts Receivable
-1,2752,156-850.77-1,665-1,373-633.42
Change in Inventory
287.81-447.43-181.33-623.18-313.29-1,125
Change in Accounts Payable
392.69-127.59346.45-659.57648.39-980.98
Change in Unearned Revenue
-53.41-10.7832.93-69.3320-9.74
Change in Other Net Operating Assets
-635.49188.33-59.23-420.87108.67-83.63
Operating Cash Flow
3,8377,4826,1551,6143,719119.66
Operating Cash Flow Growth
-50.03%21.56%281.29%-56.60%3008.27%-93.86%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-1,526-1,320-353.84-410.57-577.16-572.73
Sale of Property, Plant & Equipment
2.460.160.611.259.380.11
Cash Acquisitions
-9,407-8,134-1,242---
Sale (Purchase) of Intangibles
-3,424-3,033-1,112-2,864-2,492-1,043
Investment in Securities
-----1,583-
Other Investing Activities
-46.6319.2115.8224.48-13.3838.8
Investing Cash Flow
-14,401-12,468-2,691-3,249-4,656-1,577

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-3,9002,3781,2161,4351,291
Long-Term Debt Issued
-21,7222,95120,4766,2505,063
Total Debt Issued
30,00925,6225,32821,6927,6856,354
Short-Term Debt Repaid
--4,004-1,260-861.82-2,100-870.8
Long-Term Debt Repaid
--12,428-2,123-18,522-3,259-5,642
Lease Payments
-173.37-114.08-112.18-107.72-83.91-71.35
Total Debt Repaid
-18,229-16,432-3,382-19,384-5,359-6,513
Net Debt Issued (Repaid)
11,7809,1901,9462,3082,326-159.41
Issuance of Common Stock
9.396.770.260.6-1,414
Repurchase of Common Stock
--780.99----57.35
Common Dividends Paid
--1,520-1,232-906.23-506.06-92.01
Other Financing Activities
---0.31--558.27558.31
Financing Cash Flow
11,7896,896714.091,4031,2621,663

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
364.17-200.738119.9152.89-89.52
Net Cash Flow
1,5891,7104,259-212.5377.89116.49

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
2,3116,1625,8011,2043,142-453.07
Free Cash Flow Growth
-68.49%6.23%381.96%-61.70%--
Free Cash Flow Margin
7.44%30.05%31.21%7.10%21.47%-3.58%
Free Cash Flow Per Share
8.7323.2521.744.5411.85-1.74
Levered Free Cash Flow
494.843,3683,200-4,2961,917-1,801
Unlevered Free Cash Flow
3,0983,9163,551-3,9632,139-1,634
Free Cash Flow After Leases
2,1386,0485,6891,0963,058-524.41

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
3,1281,107495.06446.25290.7227.93
Cash Income Tax Paid
1,4971,301915.241,036444.89259.57
Change in Working Capital
-1,2841,758-711.95-3,438-909.7-2,833